Skip to main content

In the ever-evolving landscape of healthcare, breakthroughs in technology play a pivotal role in transforming patient outcomes. Lumea, a distinguished digital pathology company, is gearing up to showcase its cutting-edge solutions at the 2024 Solaris Health Annual Meeting this weekend.

Event Details:

Scheduled over January 19-20, 2024, at the Intercontinental Miami, the Solaris Health Annual Meeting is set to provide a platform for thought leaders, healthcare professionals, and companies like Lumea to engage in meaningful discussions. The balanced program, encompassing both clinical and operational topics, is designed to address the holistic needs of physicians and administrators.

Lumea: A Beacon of Innovation

As attendees navigate the bustling atmosphere of the Annual Meeting, Lumea’s presence is sure to stand out. Lumea has established itself as a trailblazer in the realm of digital pathology and pre-analytical technology since its humble beginnings more than 10 years ago. With a focus on leveraging technology to enhance diagnostic capabilities, the company’s booth at this meeting will serve as a hub of innovation. Conference-goers can expect to gain valuable insights into how Lumea’s solutions are reshaping the landscape of urology practices, ultimately contributing to improved patient care.

Stay tuned on our social media for updates from Miami, and be sure to stop by Lumea’s booth to see our tech in action.


Don’t just take it from us that our tech can benefit your practice. Here’s what uropathologist Adam Cole, MD has to say about Lumea: “We’re all doctors. We all got into this field for a reason: the patient is central to everything we do. Using Lumea technology simply results in a better end product for our patients,” said Dr. Cole. Read Dr. Cole’s story.

Urologist Dr. Ashley Ross also uses Lumea’s unique pre-analytical technology to get better results for his patients in Texas. He said, “Lumea is forward-thinking. They look at the entire process from beginning to end to make the best diagnosis possible for each patient.” Read Dr. Ross’ story.

Learn more about our unique tissue-handling technologies, which have reduced biohazard waste by 136%, formalin by 89%, containers by 83%, and have improved overall needle-core biopsy length on the final slide. They have also helped improve cancer detection rates, increase lab and pathologist efficiency, and improve workflow across the board from the surgery center through final sign-out and ancillary testing.


Leave a Reply